Literature DB >> 114347

Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.

K Whaley, P H Schur, S Ruddy.   

Abstract

Serum concentrations of C4, C3, factor B (B), properdin (P), C3b inactivator (C3bINA) and beta 1H globulin have been measured by radial immunodiffusion in sixty-two samples from thirteen patients with systemic lupus erythematosus (SLE). Significant reductions in the mean serum concentrations of C4 (classical pathway) B and P (alternative pathway) and C3 were found. In addition, the mean level of the control protein beta 1H, but not C3bINA, was reduced. Sera from thirteen patients taking during disease exacerbation (low C3) showed significantly lower levels of both C3bINA and beta 1H than sera taken from the same thirteen patients during disease remission (high C3). Serum concentrations of C3bINA correlated with B (P less than 0.005) but not C4, C3 or P, whereas levels of beta 1H correlated with C4 (P less than 0.01), B (P less than 0.005) and properdin (P less than 0.01). Serial measurements of the serum concentrations of C3bINA and beta 1H showed that levels of these protein fell during exacerbation, and such falls were more closely associated with diseases in the serum levels of the alternative pathways proteins than C4. It is concluded from these observations that serum concentrations of the control proteins C3bINA and beta 1H, especially the latter, control the extent of turnover of the alternative pathway in SLE. Metabolic studies are required to determine the causes of the decreased serum concentrations of these control proteins.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114347      PMCID: PMC1537743     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus.

Authors:  D Koffler; V Agnello; R I Carr; H G Kunkel
Journal:  Am J Pathol       Date:  1969-09       Impact factor: 4.307

3.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

4.  Studies of serum complement in the hypocomplementaemic nephritides.

Authors:  D G Williams; D K Peters; J Fallows; A Petrie; O Kourilsky; L Morel-Maroger; J S Cameron
Journal:  Clin Exp Immunol       Date:  1974-11       Impact factor: 4.330

5.  Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.

Authors:  L G Hunsicker; S Ruddy; C B Carpenter; P H Schur; J P Merrill; H J Müller-Eberhard; K F Austen
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

6.  Metabolism of properdin in normal subjects and patients with renal disease.

Authors:  J B Ziegler; F S Rosen; C A Alper; W Grupe; I H Lepow
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

7.  Glomerular complement components in human glomerulonephritis.

Authors:  P J Verroust; C B Wilson; N R Cooper; T S Edgington; F J Dixon
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

8.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

9.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

10.  Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

View more
  6 in total

1.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

2.  Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.

Authors:  J A Charlesworth; P W Peake; J Golding; J D Mackie; B A Pussell; V Timmermans; D Wakefield
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

3.  Partial H (beta 1H) deficiency and glomerulonephritis in two families.

Authors:  R J Wyatt; B A Julian; A Weinstein; N F Rothfield; R H McLean
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

4.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

5.  Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; J Hermans; L A van Es; A Cats
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

6.  Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes.

Authors:  K Whaley
Journal:  J Exp Med       Date:  1980-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.